Ocuphire Pharma announced that clinical data from its ZETA-1 trial on a person-level scale evaluating APX3330 in diabetic retinopathy were presented at the 21st Annual Angiogenesis, Exudation, and Degeneration 2024 Conference, which took place virtually on Saturday, February 3, 2024. The presentation was titled APX3330 Oral Treatment to Slow the Progression of Diabetic Retinopathy Using a Binocular DRSS Severity Scale as a Registrational Endpoint. Presentation Highlights: ZETA-1 was a Phase 2 trial of oral APX3330 in DR. It was a multi-center, randomized, double-masked, placebo-controlled trial that enrolled 103 subjects. Topline results were announced by Ocuphire in January 2023. In November, a successful end-of-phase 2 meeting outcome was announced with an agreement on Phase 3 primary endpoint of 3-step worsening on a binocular 17-step person-level scale using the Diabetic Retinopathy Severity Scale. Analysis of ZETA-1 Phase 2 results using the person-level scale, showed only 5% of subjects treated with APX3330 had a clinically meaningful greater than or equal to 3-step worsening in DRSS at Week 24 on this binocular person-level scale, compared with 13% of placebo patients. APX3330 showed favorable safety and tolerability in diabetic patients that continued dosing their medications through the study durations to manage their diabetic comorbidities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OCUP:
- Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
- Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma files $175M mixed securities shelf
- Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
- Ocuphire Pharma receives FDA agreement under SPA for LYNX-2 Phase 3 trial